Long term safety and efficacy of peginterferon beta-1a in patients with relapsing remitting multiple sclerosis
Latest Information Update: 26 Oct 2018
Price :
$35 *
At a glance
- Drugs Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms IMSE 6
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 22 Nov 2017 New trial record
- 28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis